This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: "Somatrem" – news · newspapers · books · scholar · JSTOR (June 2019) (Learn how and when to remove this template message)
Somatrem
Clinical data
Trade namesProtropin
AHFS/Drugs.comMicromedex Detailed Consumer Information
ATC code
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC995H1537N263O301S8
Molar mass22256.26 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Somatrem, sold under the brand name Protropin, is an analogue of growth hormone (GH).[1]

Overview

Somatrem is a recombinant human growth hormone used for the treatment of short stature due to decreased or absent secretion of endogenous growth hormone.

Somatrem was first marketed under the brand name Protropin by Genentech in 1985.[2] It differs from endogenous growth hormone by the addition of an extra methionine at the N-terminus[3][circular reference].

Somatrem has largely been replaced by somatropin, marketed by several companies including by Genentech as the brand Nutropin.

References

  1. ^ Flodh H (1987). "Present situation worldwide regarding the use and clinical experience of Somatonorm (somatrem)". Acta Paediatrica Scandinavica. Supplement. 331: 1–4. doi:10.1111/j.1651-2227.1987.tb17089.x. PMID 3300150. S2CID 20410776.
  2. ^ "Genentech: Press Releases - Friday, Oct 18, 1985". www.gene.com.
  3. ^ Growth hormone therapy#cite note-32

External links

GH/IGF-1 axis signaling modulators
Hypothalamic-pituitary hormones and analogues (H01)
More
Categories